|
1
|
Sethi N and Kang Y: Unravelling the
complexity of metastasis -molecular understanding and targeted
therapies. Nat Rev Cancer. 11:735–748. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu Y, Liang H, Yu T, Xie J, Chen S, Dong
H, Sinko PJ, Lian S, Xu J, Wang J, et al: Isolation and
characterization of living circulating tumor cells in patients by
immunomagnetic negative enrichment coupled with flow cytometry.
Cancer. 121:3036–3045. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Labelle M and Hynes RO: The initial hours
of metastasis: The importance of cooperative host-tumor cell
interactions during hematogenous dissemination. Cancer Discov.
2:1091–1099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boroughs LK and DeBerardinis RJ: Metabolic
pathways promoting cancer cell survival and growth. Nat Cell Biol.
17:351–359. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Loo JM, Scherl A, Nguyen A, Man FY,
Weinberg E, Zeng Z, Saltz L, Paty PB and Tavazoie SF: Extracellular
metabolic energetics can promote cancer progression. Cell.
160:393–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Phan L, Chou PC, Velazquez-Torres G,
Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, et
al: The cell cycle regulator 14-3-3σ opposes and reverses cancer
metabolic reprogramming. Nat Commun. 6:75302015. View Article : Google Scholar
|
|
11
|
Phan LM, Yeung SC and Lee MH: Cancer
metabolic reprogramming: Importance, main features, and potentials
for precise targeted anti-cancer therapies. Cancer Biol Med.
11:1–19. 2014.PubMed/NCBI
|
|
12
|
Zheng J: Energy metabolism of cancer:
Glycolysis versus oxidative phosphorylation (Review). Oncol Lett.
4:1151–1157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buchakjian MR and Kornbluth S: The engine
driving the ship: Metabolic steering of cell proliferation and
death. Nat Rev Mol Cell Biol. 11:715–727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alderton GK: Metastasis: Metabolic
reprogramming in disseminated cells. Nat Rev Cancer. 14:7032014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Postovit LM, Adams MA, Lash GE, Heaton JP
and Graham CH: Oxygen-mediated regulation of tumor cell
invasiveness. Involvement of a nitric oxide signaling pathway. J
Biol Chem. 277:35730–35737. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Asnaghi L, Gezgin G, Tripathy A, Handa JT,
Merbs SL, van der Velden PA, Jager MJ, Harbour JW and Eberhart CG:
EMT-associated factors promote invasive properties of uveal
melanoma cells. Mol Vis. 21:919–929. 2015.PubMed/NCBI
|
|
19
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM and
Pardee AB: Drg-1 as a differentiation-related, putative metastatic
suppressor gene in human colon cancer. Cancer Res. 60:749–755.
2000.PubMed/NCBI
|
|
23
|
Lu Y, Yu T, Liang H, Wang J, Xie J, Shao
J, Gao Y, Yu S, Chen S, Wang L, et al: Nitric oxide inhibits
hetero-adhesion of cancer cells to endothelial cells: Restraining
circulating tumor cells from initiating metastatic cascade. Sci
Rep. 4:43442014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lian S, Lu Y, Cheng Y, Yu T, Xie X, Liang
H, Ye Y and Jia L: S-nitrosocaptopril interrupts adhesion of cancer
cells to vascular endothelium by suppressing cell adhesion
molecules via inhibition of the NF-KB and JAK/STAT signal pathways
in endothelial cells. Eur J Pharmacol. 791:62–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wick AN, Drury DR, Nakada HI and Wolfe JB:
Localization of the primary metabolic block produced by
2-deoxyglucose. J Biol Chem. 224:963–969. 1957.PubMed/NCBI
|
|
28
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Elledge SJ: Cell cycle checkpoints:
Preventing an identity crisis. Science. 274:1664–1672. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shin I, Yakes FM, Rojo F, Shin NY, Bakin
AV, Baselga J and Arteaga CL: PKB/Akt mediates cell-cycle
progression by phosphorylation of p27(Kip1) at threonine 157 and
modulation of its cellular localization. Nat Med. 8:1145–1152.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sheaff RJ, Singer JD, Swanger J,
Smitherman M, Roberts JM and Clurman BE: Proteasomal turnover of
p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell.
5:403–410. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gottlieb E, Armour SM, Harris MH and
Thompson CB: Mitochondrial membrane potential regulates matrix
configuration and cytochrome c release during apoptosis. Cell Death
Differ. 10:709–717. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Beltrán B, Mathur A, Duchen MR,
Erusalimsky JD and Moncada S: The effect of nitric oxide on cell
respiration: A key to understanding its role in cell survival or
death. Proc Natl Acad Sci USA. 97:14602–14607. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gstraunthaler G: Alternatives to the use
of fetal bovine serum: Serum-free cell culture. ALTEX. 20:275–281.
2003.PubMed/NCBI
|
|
36
|
Shiraishi T, Verdone JE, Huang J, Kahlert
UD, Hernandez JR, Torga G, Zarif JC, Epstein T, Gatenby R,
McCartney A, et al: Glycolysis is the primary bioenergetic pathway
for cell motility and cytoskeletal remodeling in human prostate and
breast cancer cells. Oncotarget. 6:130–143. 2015. View Article : Google Scholar :
|
|
37
|
Cárdenas ML, Cornish-Bowden A and Ureta T:
Evolution and regulatory role of the hexokinases. Biochim Biophys
Acta. 1401:242–264. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pastorino JG and Hoek JB: Hexokinase II:
The integration of energy metabolism and control of apoptosis. Curr
Med Chem. 10:1535–1551. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roberts DJ, Tan-Sah VP, Ding EY, Smith JM
and Miyamoto S: Hexokinase-II positively regulates glucose
starvation-induced autophagy through TORC1 inhibition. Mol Cell.
53:521–533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tan VP and Miyamoto S: HK2/hexokinase-II
integrates glycolysis and autophagy to confer cellular protection.
Autophagy. 11:963–964. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miyamoto S, Murphy AN and Brown JH: Akt
mediates mitochondrial protection in cardiomyocytes through
phosphorylation of mitochondrial hexokinase-II. Cell Death Differ.
15:521–529. 2008. View Article : Google Scholar
|
|
42
|
Sun L, Shukair S, Naik TJ, Moazed F and
Ardehali H: Glucose phosphorylation and mitochondrial binding are
required for the protective effects of hexokinases I and II. Mol
Cell Biol. 28:1007–1017. 2008. View Article : Google Scholar :
|
|
43
|
Robey RB and Hay N: Mitochondrial
hexokinases, novel mediators of the antiapoptotic effects of growth
factors and Akt. Oncogene. 25:4683–4696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pastorino JG, Shulga N and Hoek JB:
Mitochondrial binding of hexokinase II inhibits Bax-induced
cytochrome c release and apoptosis. J Biol Chem. 277:7610–7618.
2002. View Article : Google Scholar
|
|
45
|
Semenza GL: Tumor metabolism: Cancer cells
give and take lactate. J Clin Invest. 118:3835–3837.
2008.PubMed/NCBI
|
|
46
|
Faubert B, Vincent EE, Griss T, Samborska
B, Izreig S, Svensson RU, Mamer OA, Avizonis D, Shackelford DB,
Shaw RJ, et al: Loss of the tumor suppressor LKB1 promotes
metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad
Sci USA. 111:2554–2559. 2014. View Article : Google Scholar
|
|
47
|
Semenza GL, Jiang BH, Leung SW, Passantino
R, Concordet JP, Maire P and Giallongo A: Hypoxia response elements
in the aldolase A, enolase 1, and lactate dehydrogenase A gene
promoters contain essential binding sites for hypoxia-inducible
factor 1. J Biol Chem. 271:32529–32537. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim JW, Tchernyshyov I, Semenza GL and
Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase
kinase: A metabolic switch required for cellular adaptation to
hypoxia. Cell Metab. 3:177–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Papandreou I, Cairns RA, Fontana L, Lim AL
and Denko NC: HIF-1 mediates adaptation to hypoxia by actively
downregulating mitochondrial oxygen consumption. Cell Metab.
3:187–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang H, Bosch-Marce M, Shimoda LA, Tan
YS, Baek JH, Wesley JB, Gonzalez FJ and Semenza GL: Mitochondrial
autophagy is an HIF-1-dependent adaptive metabolic response to
hypoxia. J Biol Chem. 283:10892–10903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Du L, Wang H, He L, Zhang J, Ni B, Wang X,
Jin H, Cahuzac N, Mehrpour M, Lu Y, et al: CD44 is of functional
importance for colorectal cancer stem cells. Clin Cancer Res.
14:6751–6760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: CD133 expression is an independent prognostic marker for
low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lunter PC, van Kilsdonk JW, van Beek H,
Cornelissen IM, Bergers M, Willems PH, van Muijen GN and Swart GW:
Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a
novel actor in invasive growth, controls matrix metalloproteinase
activity. Cancer Res. 65:8801–8808. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Levin TG, Powell AE, Davies PS, Silk AD,
Dismuke AD, Anderson EC, Swain JR and Wong MH: Characterization of
the intestinal cancer stem cell marker CD166 in the human and mouse
gastrointestinal tract. Gastroenterology. 139:2072–2082.e2075.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hansen AG, Arnold SA, Jiang M, Palmer TD,
Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, et al:
ALCAM/ CD166 is a TGF-β-responsive marker and functional regulator
of prostate cancer metastasis to bone. Cancer Res. 74:1404–1415.
2014. View Article : Google Scholar : PubMed/NCBI
|
